In order to commercialize Lactobacillus plantarum DMDL9010， the experiment was optimized by Plackett-Burman experiment and Box-Behnken experiment. This experiment mainly evaluated the safety of Lactobacillus plantarum DMDL9010 and provided the security for the production and application. Through harmful melabolite experiments， drug resistance experiments and other evaluation experiments determined the strains of bacteria as edible safety bacteria. The results showed that when the optimum dosage of Lactobacillus plantarum DMDL 9010 medium was 5 g/L of soybean polypeptide， 0.01% of vitamin C and 0.1565 g/L of manganese sulfate， the optimum dosage of Lactobacillus plantarum DMDL 9010 was 4.05×1010 CFU/mL， and the validation test was 3.88×1010 CFU/mL， which was close to the theoretical value. The safety evaluation experiments showed that the detection results of the harmful metabolites were all negative. Among the four common antibiotics， tetracycline， Mycin appears safe for the sensitive， erythromycin， amoxicillin showed safe and sensitive and contain no plasmid； Lactobacillus plantarum DMDL 9010 can inhibit the growth of E. coli， Staphylococcus aureus， Listeria monocytogenes； Did not produce hemolysis phenomenon. The results provide a reference for the commercial application of Lactobacillus plantarum DMDL 9010 in food field.